Craft

Fulcrum Therapeutics

Stock Price

$7.5

2024-05-07

Market Capitalization

$468.6 M

2024-05-07

Revenue

$2.8 M

FY, 2023

Fulcrum Therapeutics Summary

Company Summary

Overview
The sequencing of the human genome has provided incredible insight into disease biology, yet the richness of biology comes from the dynamic on and off switches that control the genome – gene regulation. The Fulcrum product engine is based on the breakthrough biology of gene regulation. It will bring to bear medicines for devastating diseases across multiple therapeutic areas by modulating – or balancing – the expression of the genes known to drive disease. By focusing on disease causative genes, we are taking a highly personalized approach to treating disease – unlocking the druggable mechanisms that regulate disease genes to develop a new generation of disease-modifying therapies.
Type
Public
Status
Active
Founded
2016
HQ
Cambridge, MA, US | view all locations
Website
http://www.fulcrumtx.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Robert J. Gould
  • Mel Hayes

    Mel Hayes, Executive Vice President, Patient Experience

  • Curtis Oltmans

    Curtis Oltmans, Chief Legal Officer

  • Kim Hazen

LocationsView all

1 location detected

  • Cambridge, MA HQ

    United States

    26 Landsdowne St

Fulcrum Therapeutics Financials

Summary Financials

Revenue (FY, 2023)
$2.8M
Net income (FY, 2023)
($97.3M)
Cash (FY, 2023)
$25.6M
EBIT (FY, 2023)
($110.7M)
Enterprise value
$453.9M

Footer menu